Jean-Pierre Valentin
Overview
Explore the profile of Jean-Pierre Valentin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
111
Citations
1244
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Valentin J, Leishman D
Regul Toxicol Pharmacol
. 2025 Mar;
:105795.
PMID: 40057171
Although the ICH S7A guideline on safety pharmacology largely achieved its objective, a proportion of remaining adverse drug reactions and attrition can be attributed in part to gaps in safety...
2.
Chaudhary K, Clancy C, Yang P, Pierson J, Goldin A, Koerner J, et al.
Clin Transl Sci
. 2024 Dec;
17(12):e70098.
PMID: 39660576
The human voltage-gated sodium channel Na1.5 (hNa1.5/SCN5A) plays a critical role in the initiation and propagation of action potentials in cardiac myocytes, and its modulation by various drugs has significant...
3.
Hewitt P, Hartmann A, Tornesi B, Ferry-Martin S, Valentin J, Desert P, et al.
Regul Toxicol Pharmacol
. 2024 Nov;
154:105736.
PMID: 39515409
Malaria is an acute, debilitating parasitic illness. There were 249 million cases of malaria in 2022, resulting in 608,000 deaths globally, 76% of which were children ≤5 years. The unique...
4.
Boulay E, Authier S, Bartko T, Greiter-Wilke A, Leishman D, Li D, et al.
J Pharmacol Toxicol Methods
. 2024 Jul;
129:107543.
PMID: 39019200
Introduction: Corrected QT interval (QTc)is an established biomarker for drug-induced Torsade de Pointe (TdP), but with concerns for a false positive signal. Clinically, JTpc and TpTec have emerged as ECG...
5.
Gerets H, Delaunois A, Cardenas A, Class R, Fleurance R, de Haro T, et al.
Toxicol Sci
. 2024 Jul;
201(2):311-320.
PMID: 38976649
Within drug development, high off-target promiscuity as well as potent cytotoxicity, are associated with a high attrition rate. We investigated the safety profile of novel plasmepsin X (PMX) inhibitors for...
6.
Delaunois A, Cardenas A, de Haro T, Gerets H, Gryshkova V, Hebeisen S, et al.
Toxicol Sci
. 2024 Jul;
201(2):321-330.
PMID: 38976647
Quinoline-related antimalarial drugs have been associated with cardiotoxicity risk, in particular QT prolongation and QRS complex widening. In collaboration with Medicines for Malaria Venture, we discovered novel plasmepsin X (PMX)...
7.
Pawluk E, Delaunois A, Gamboa B, Valentin J
J Pharmacol Toxicol Methods
. 2024 Jul;
128:107537.
PMID: 38955286
Our study retrospectively examines 51 non-rodent general toxicology studies conducted over the past 8 years to ascertain the influence of recording methodologies on baseline cardiovascular (CV) parameters and statistical sensitivity....
8.
Brennan R, Jenkinson S, Brown A, Delaunois A, Dumotier B, Pannirselvam M, et al.
Nat Rev Drug Discov
. 2024 Jun;
23(7):563.
PMID: 38886593
No abstract available.
9.
Brennan R, Jenkinson S, Brown A, Delaunois A, Dumotier B, Pannirselvam M, et al.
Nat Rev Drug Discov
. 2024 May;
23(7):525-545.
PMID: 38773351
Secondary pharmacology screening of investigational small-molecule drugs for potentially adverse off-target activities has become standard practice in pharmaceutical research and development, and regulatory agencies are increasingly requesting data on activity...
10.
Pierson J, Berridge B, Blinova K, Brooks M, Eldridge S, OBrien C, et al.
J Pharmacol Toxicol Methods
. 2024 May;
127:107511.
PMID: 38710237
The Health and Environmental Sciences Institute (HESI) is a nonprofit organization dedicated to resolving global health challenges through collaborative scientific efforts across academia, regulatory authorities and the private sector. Collaborative...